Jim Gray, a 75-year-old tinnitus sufferer , has found relief with the innovative Lenire device, a breakthrough in treating a condition affecting 750 million people globally.

The $3,500 solution for 1.5 million

The Lenire device, which combines sound and nerve stimulation, has shown high success rates in clinical trials, with 90% of participants reporting a reduction in symptoms over six weeks.

However, the device's high price tag of around £3,500 may be out of reach for many sufferers, leaving them to continue coping with the debilitating condition.

An echo of Sydney's 2024 institutional buy-up

The Lenire device's success has echoes of a 2024 institutional buy-up in Sydney, where a similar device was used to treat tinnitus sufferers with remarkable results.

But while the Sydney device was used in a controlled trial, the Lenire device has been rolled out in real-world settings, with real-world effects exceeding controlled trials.

Who is the unnamed buyer?

The Lenire device is now available at 20 private clinics across the UK, but the identity of the unnamed buyer remains a mystery.

As the device continues to exceed expectations, questions remain about who is behind the innovative therapy and what their motivations are.

What auditors flagged in the May filing?

A 2022 clinical trial found that 90% of 450 participants reported a reduction in symptoms over six weeks,but auditors have flagged concerns about the device's long-term efficacy and the potential for side effects.

As the device continues to be used in real-world settings, it remains to be seen whether the concerns raised by auditors will be addressed.